Bio-link Australia Pty. Ltd.


The Bio-Link Team, located in our Melbourne and Sydney offices, consist of two executive directors, complemented by talented employees and interns, who work together to provide professional, cost effective and transparent services to our clients.

Bio-Link team photo
From Left: Poornima Ravi, Oliver Croad, Christopher Boyer, Gorjana Mitic, Karen Li, Andrew Coley, Christian Toouli
(Absent: Lilly Bojarski, Jonathan Nambier and Christos Papadimitirou)

Mr Christopher Boyer - Executive Director

Christopher specialises in the selling of biotechnology, as the culmination of his 20+ year career spanning its discovery, development and commercialisation. Most recently, as Executive Director of Bio-Link, Christopher led licensing efforts for a range of drug and diagnostic opportunities and closed several deals.

Prior to joining Bio-Link, Christopher served as Business Development Manager at Cryptome Pharmaceuticals, a peptide therapeutics developer in Melbourne. Earlier he was Manager, Corporate and Strategic Development at NewBiotics, a San Diego drug developer, where he negotiated contracts and contributed to a $20M co-development deal for cancer chemotherapeutics. Christopher also consulted to San Diego’s Halozyme Therapeutics, a developer of therapeutic enzymes, preparing project valuations to support a successful $9.2M Series A financing.

Christopher draws upon deep technical insights acquired during his extensive R&D experience in small molecule drug discovery and molecular neuroscience, attained at Novartis and the Howard Hughes Medical Institute respectively. He earned a BS in Animal Physiology and Neuroscience from the University of California, San Diego, and augmented his business skills with an MBA in Marketing from the University of San Diego.


Dr Christian Toouli - Executive Director

Christian is a motivated and resourceful Commercialisation Executive, dedicated to identifying, developing and generating value from biotechnology intellectual property.

As Co-Founder and Executive Director of Bio-Link Australia, Christian has worked with many of the company’s Australian and international drug discovery and development clients. Accessing a large network of contacts from throughout the global biopharmaceutical industry, and with broad business development, project management and scientific expertise, he has facilitated numerous technology evaluation, IP licensing and partnering deals with international life sciences and biopharmaceutical companies.

Previously, Christian was a Postdoctoral Fellow in the Discovery Research Department of Schering-Plough Biopharma/DNAX Research Institute, the biotechnology arm of Schering-Plough Corporation. In this capacity, he investigated novel targets for oncology therapeutics and undertook competitive intelligence analyses for senior management.

During this time, Christian also served as the United States National and San Francisco Regional Life Sciences Co-Chair for Advance, the Australian expatriate professional network in the United States. Christian received his PhD from the University of Sydney for his research into cellular immortalisation and telomere maintenance at the Children’s Medical Research Institute. He was awarded a Certificate in Biotechnology Management with Honours from the University of California, Santa Cruz Extension, and First-Class Honours in Biotechnology from Flinders University of South Australia. Christian is also a graduate of the Australian Institute of Company Directors.

Dr Daniella Goldberg - PR and Communications Manager

Daniella offers a unique skillset; combining her science, business and communications expertise to the Bio-Link team and clients. She has a passion for turning complex scientific research announcements into compelling news for TV, radio, print and online media.

Daniella’s research career focused on stem cell and transplant biology, prior to transitioning into science journalism, leading to the establishment of her own communications consulting business. She has over 20 years of experience working in the media and as a specialist communications consultant.

Throughout her career, Daniella has consulted to global healthcare communications agencies and life sciences businesses including pharmaceutical, biotechnology and medical device (public & private) companies, medical research and not-for-profit organisations. Her client portfolio focuses on health, science, medicine and wellness, aimed at strategically positioning and conveying science and innovation to sophisticated and lay audiences.

Daniella is co-founder and a Non-Executive Director of the New South Wales Stem Cell Network, an organisation that has been instrumental in progressing stem cell research from the lab to the clinic in Australia. Her original cell therapy research at the Garvan Institute of Medical Research led to the award of a Doctorate of Medicine from the University of NSW. Daniella subsequently augmented her research credentials with a Diploma of Communications from the University of Technology, Sydney.

Daniella is passionate about integrating her medical science, business and communications skills to offer a valuable communications package to innovative research organisations globally.


Dr Jonathan Nambiar - Business Development Manager

Jonathan joined Bio-Link in January 2018 as a Business Development Manager. He has a wide-ranging background in investment analysis, pre-clinical drug development, and biomedical research.

Prior to Bio-Link, Jonathan worked for 3 years as an investment analyst in the healthcare team at Magellan Financial Group, an equities fund manager with over $50 billion under management. At Magellan, Jonathan was part of the team which built coverage of the major US- and European-domiciled global pharmaceutical and biotechnology companies, including Novartis, Sanofi and Johnson & Johnson. He was responsible for communicating the investment thesis for healthcare investments to Magellan’s investment committee. This included framing bio-pharmaceutical market dynamics, communicating principles of pharmacology and physiology for investors, and providing stock recommendations based on valuation and analysis of the implications of news flow.

Prior to Magellan, Jonathan worked for 4 years in biologics R&D at Teva Pharmaceuticals Australia (formerly known as Cephalon Australia and Arana Therapeutics Ltd). Jonathan was part of the team which became Teva Pharmaceuticals Australia, following Teva’s acquisition of Cephalon in 2011. At Cephalon and Teva, Jonathan worked in lead discovery and development for programs in respiratory, oncology and immunology therapeutic areas. He was promoted to senior research scientist in early 2014.

Jonathan earned a PhD in immunology and infectious diseases from the University of Sydney Medical School, for work on vaccine approaches and cellular immune responses to tuberculosis. He also holds a Bachelor of Medical Science with First Class Honours, a Graduate Certificate in Innovation and Enterprise, both from the University of Sydney, and an MBA from the University of Newcastle, Australia.


Dr Christos Papadimitriou - Business Development Manager

Christos’ background extends from conducting primary research under laboratory conditions to identifying commercial opportunities and creating spin-out entities to commercialise new IP in the Pharmaceuticals/Health Care space.

He is an award-winning inventor of a drug-screening method that delivers up to a four-fold increase in the validation efficiency of a compound’s lead target, enabling a 75% cost reduction. His earlier projects include the development of hydrogel scaffolds for tissue engineering and regenerative medicine purposes, and the development of artificial intelligence Hospital Information System (HIS) modules with a related smart phone-based records management solution. These AI technologies were developed based on stakeholder and legal requirements to deliver a 35% increase in personnel efficiency in hospital emergency units.

Christos earned a Ph.D. in Neuroscience from the University of Dresden and the German Center for Neurodegenerative Diseases. He has designed research projects with commercial potential for world-class institutes including Johns Hopkins University, ETH Zurich and EMBL Heidelberg, where his capabilities and entrepreneurial spirit have been recognised through prestigious scholarships and awards.


Dr Lilly Bojarski - Senior Business Development Associate

Lilly received a Bachelor of Science and Masters of Science degrees in toxicology from the University of Guelph, in Canada, prior to moving to New Zealand where she completed a cross-disciplinary PhD at the University of Auckland. Her thesis research addressed questions of nutritional chemistry, bacterial genetics, gut microbiome structure and function, and microbial metagenomics. Between the Bachelors and Masters degrees she was introduced to scientific commercialisation whilst working as a visiting scientist at AgResearch, a Crown Research Institute in New Zealand.

After completing the Bio-Link Internship Program Lilly has continued to work as a Business Development Associate, working with management to conduct IP and competitor landscape surveys, producing commercial opportunity summaries and other reports, and working with clients. While not at Bio-Link, Lilly is involved in conducting fundamental studies of gene regulation using emerging next-generation sequencing technologies at the Garvan Institute of Medical Research, and manages the busy lab of its Director.